The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tissue concentration of systemically administered antineoplastic agents in human brain tumors
Open accessAbstract
The blood–brain-barrier (BBB) limits the penetration of many systemic antineoplastic therapies. Consequently, many agents may be used in clinical studies and clinical practice though they may not achieve therapeutic levels within the tumor. We sought to compile the currently available human data on antineoplastic drug concentrations in brain and tumor tissue according to BBB status. A review of the literature was conducted for human studies providing concentrations of antineoplastic agents in blood and metastatic brain tumors or high-grade gliomas. Studies were considered optimal if they reported simultaneous tissue and blood concentration, multiple sampling times and locations, MRI localization, BBB status at sampling site, tumor histology, and individual subject data. Twenty-Four studies of 19 compounds were included. These examined 18 agents in contrast-enhancing regions of high-grade gliomas, with optimal data for 2. For metastatic brain tumors, adequate data was found for 9 agents. Considerable heterogeneity was found in the measurement value, tumor type, measurement timing, and sampling location within and among studies, limiting the applicability of the results. Tissue to blood ratios ranged from 0.054 for carboplatin to 34 for mitoxantrone in high-grade gliomas, and were lowest for temozolomide (0.118) and etoposide (0.116), and highest for mitoxantrone (32.02) in metastatic tumors. The available data examining the concentration of antineoplastic agents in brain and tumor tissue is sparse and limited by considerable heterogeneity. More studies with careful quantification of antineoplastic agents in brain and tumor tissue is required for the rational development of therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abbott, N. J. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.014 · Cited by 181
Cited by
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Chen, Q., Boire, A., Jin, X., Valiente, M., Er, E. E., Lopez-Soto, A., S. Jacob, L., Patwa, R., Shah, H., Xu, K., et al. (2016) · Nature · doi:10.1038/nature18268 · Cited by 969
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
Lin, X., & DeAngelis, L. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9503 · Cited by 441
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Metadata
- Authors
- Pitz, M. W., Desai, A., Grossman, S. A., & Blakeley, J. O.
- Venue
- Journal of Neuro-Oncology
- Published
- 2011-03-12
- Volume
- 104
- Issue
- 3
- Pages
- 629-638
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W2021880945
- Cited by
- 161
- References
- 1
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue concentration of systemically administered antineoplastic agents in human brain tumors. https://app.cochat.ai/papers/10.1007/s11060-011-0564-y
- The paper
- Pitz, M. W., Desai, A., Grossman, S. A., & Blakeley, J. O. (2011). Tissue concentration of systemically administered antineoplastic agents in human brain tumors. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-011-0564-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.